ATE463498T1 - Imidazo-verbindungen - Google Patents

Imidazo-verbindungen

Info

Publication number
ATE463498T1
ATE463498T1 AT07728054T AT07728054T ATE463498T1 AT E463498 T1 ATE463498 T1 AT E463498T1 AT 07728054 T AT07728054 T AT 07728054T AT 07728054 T AT07728054 T AT 07728054T AT E463498 T1 ATE463498 T1 AT E463498T1
Authority
AT
Austria
Prior art keywords
imidazo compounds
imidazo
compounds
Prior art date
Application number
AT07728054T
Other languages
English (en)
Inventor
Peter Herold
Robert Mah
Vincenzo Tschinke
Aleksandar Stojanovic
Christiane Marti
Stjepan Jelakovic
Stefan Stutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE463498T1 publication Critical patent/ATE463498T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT07728054T 2006-04-12 2007-04-12 Imidazo-verbindungen ATE463498T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH6202006 2006-04-12
PCT/EP2007/053587 WO2007116101A1 (en) 2006-04-12 2007-04-12 Imidazo compounds

Publications (1)

Publication Number Publication Date
ATE463498T1 true ATE463498T1 (de) 2010-04-15

Family

ID=38462029

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07728052T ATE480545T1 (de) 2006-04-12 2007-04-12 Imidazo-verbindungen
AT07728054T ATE463498T1 (de) 2006-04-12 2007-04-12 Imidazo-verbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07728052T ATE480545T1 (de) 2006-04-12 2007-04-12 Imidazo-verbindungen

Country Status (15)

Country Link
US (3) US7879847B2 (de)
EP (2) EP2007770B1 (de)
JP (2) JP2009534319A (de)
CN (2) CN101421277A (de)
AR (1) AR060590A1 (de)
AT (2) ATE480545T1 (de)
BR (2) BRPI0710614A2 (de)
CA (2) CA2649213A1 (de)
DE (2) DE602007009074D1 (de)
ES (2) ES2342689T3 (de)
IL (2) IL194583A0 (de)
PL (2) PL2007770T3 (de)
PT (2) PT2007771E (de)
TW (1) TW200808813A (de)
WO (2) WO2007116099A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960991A (zh) * 2004-05-28 2007-05-09 斯皮德尔实验股份公司 用作醛固酮合酶抑制剂的四氢咪唑并[1,5－a]吡啶衍生物
AR056888A1 (es) * 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
MX2011012628A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
ES2582395T3 (es) 2009-05-28 2016-09-12 Novartis Ag Derivados aminobutíricos sustituidos como inhibidores de neprilisina
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
PL2729142T3 (pl) 2011-07-08 2018-10-31 Novartis Ag Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
JP6295277B2 (ja) 2013-02-14 2018-03-14 ノバルティス アーゲー Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
HUE039981T2 (hu) 2014-07-24 2019-02-28 Boehringer Ingelheim Int Aldoszteron szintáz inhibitorok
WO2016116842A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US20230089867A1 (en) 2018-11-27 2023-03-23 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
JP7530384B2 (ja) 2019-05-01 2024-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング （ｒ）－（２－メチルオキシラン－２－イル）メチル ４－ブロモベンゼンスルホネート
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
TW202339719A (zh) 2021-12-14 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療慢性腎臟病之醛固酮合成酶抑制劑
KR20260015867A (ko) 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0670064B2 (ja) * 1986-12-08 1994-09-07 三井石油化学工業株式会社 二環性イミダゾ−ル誘導体
WO1997000257A1 (en) * 1995-06-14 1997-01-03 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
AU7393801A (en) * 2000-04-12 2001-10-23 Novartis Ag Combination of organic compounds
DK1537114T3 (da) * 2002-08-07 2006-11-13 Novartis Ag Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande
TW200611898A (en) 2004-05-28 2006-04-16 Speedel Experimenta Ag Organic compounds
CN1960991A (zh) * 2004-05-28 2007-05-09 斯皮德尔实验股份公司 用作醛固酮合酶抑制剂的四氢咪唑并[1,5－a]吡啶衍生物
ATE490241T1 (de) * 2004-05-28 2010-12-15 Novartis Ag Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren
TW200611897A (en) * 2004-07-09 2006-04-16 Speedel Experimenta Ag Organic compounds
AR056888A1 (es) * 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds

Also Published As

Publication number Publication date
BRPI0711540A2 (pt) 2011-11-01
IL194584A0 (en) 2009-08-03
DE602007005788D1 (de) 2010-05-20
CN101421277A (zh) 2009-04-29
US8138176B2 (en) 2012-03-20
ES2342689T3 (es) 2010-07-12
PL2007770T3 (pl) 2011-03-31
EP2007771B1 (de) 2010-04-07
CN101421279A (zh) 2009-04-29
JP5260496B2 (ja) 2013-08-14
WO2007116099A1 (en) 2007-10-18
US20090192149A1 (en) 2009-07-30
TW200808813A (en) 2008-02-16
PT2007770E (pt) 2010-10-21
EP2007771A1 (de) 2008-12-31
ATE480545T1 (de) 2010-09-15
ES2352358T3 (es) 2011-02-17
EP2007770B1 (de) 2010-09-08
US20090192144A1 (en) 2009-07-30
CA2649217A1 (en) 2007-10-18
IL194583A0 (en) 2009-08-03
DE602007009074D1 (de) 2010-10-21
CN101421279B (zh) 2012-08-15
PL2007771T3 (pl) 2010-10-29
PT2007771E (pt) 2010-05-11
JP2009534319A (ja) 2009-09-24
US20110092492A1 (en) 2011-04-21
EP2007770A1 (de) 2008-12-31
BRPI0710614A2 (pt) 2011-08-16
WO2007116101A1 (en) 2007-10-18
US7879847B2 (en) 2011-02-01
AR060590A1 (es) 2008-07-02
CA2649213A1 (en) 2007-10-18
JP2009533395A (ja) 2009-09-17

Similar Documents

Publication Publication Date Title
FIC20220042I1 (fi) inebilizumab
LTPA2020501I1 (lt) Pakeistieji enaminokarbonilo junginiai
ATE480545T1 (de) Imidazo-verbindungen
ATE524477T1 (de) Aziridinylepothilonverbindungen
BRPI0815042A2 (pt) Compostos de pirazol
BRPI0813500A2 (pt) Compostos antivirais
BRPI0718874A2 (pt) Compostos orgânicos
BRPI0714512A2 (pt) Compostos químicos
NO20084803L (no) organiske forbindelser
BRPI0718478A2 (pt) Compostos orgânicos
BRPI0821086A2 (pt) Compostos inseticidas
DE602006004717D1 (de) Kapselperforationsmodul
AT504580A3 (de) Scan-einrichtung
DE602006021235D1 (de) Kristallglasgegenstand
BRPI0717070A2 (pt) compostos de tiofeno pirazolopirimidina
BRPI0811264A2 (pt) Compostos
BRPI0712902A2 (pt) compostos orgânicos
DE502007001629D1 (de) Rfahren
BRPI0717939A2 (pt) Aminometil-4-imidazóis
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
BRPI0809996A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila
DE502007000361D1 (de) Stanznieteinheit
BRPI0815181A2 (pt) Compostos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2007771

Country of ref document: EP